TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
|Articles|November 1, 2000
The American Journal of Managed Care
- November 2000
- Volume 6
- Issue 11
Managed Care Market Share and Cesarean Section Rates in the United States: Is There a Link?
Author(s)William J. Hueston, MD, Angela Sutton, BS
Advertisement
Articles in this issue
almost 26 years ago
Disease Management for Diabetes Mellitus: Impact on Hemoglobin A1Calmost 26 years ago
Is the Gatekeeper Just Another Buggy Whip?almost 26 years ago
Show Me the Money: Medical Directors' Responses to a Mail SurveyAdvertisement
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
3
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
4
5 Things to Know About Eye Injury Prevention Month
5